Logo image of LMDX

LUMIRADX LTD (LMDX) Stock Fundamental Analysis

NASDAQ:LMDX - Nasdaq - KYG5709L1095 - Common Stock - Currency: USD

0.016  -0.02 (-53.49%)

After market: 0.0136 0 (-15%)

Fundamental Rating

1

We assign a fundamental rating of 1 out of 10 to LMDX. LMDX was compared to 187 industry peers in the Health Care Equipment & Supplies industry. Both the profitability and financial health of LMDX have multiple concerns. LMDX is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year LMDX has reported negative net income.
LMDX had a negative operating cash flow in the past year.
In the past 5 years LMDX always reported negative net income.
In the past 5 years LMDX always reported negative operating cash flow.
LMDX Yearly Net Income VS EBIT VS OCF VS FCFLMDX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 -100M -200M -300M -400M

1.2 Ratios

LMDX's Return On Assets of -99.18% is on the low side compared to the rest of the industry. LMDX is outperformed by 82.91% of its industry peers.
Industry RankSector Rank
ROA -99.18%
ROE N/A
ROIC N/A
ROA(3y)-54.66%
ROA(5y)-52.33%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
LMDX Yearly ROA, ROE, ROICLMDX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 0 100 -100 200 300 400

1.3 Margins

LMDX does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
LMDX Yearly Profit, Operating, Gross MarginsLMDX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 0 -200 -400

More info and screens

1

2. Health

2.1 Basic Checks

LMDX does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for LMDX has been reduced compared to 1 year ago.
The debt/assets ratio for LMDX is higher compared to a year ago.
LMDX Yearly Shares OutstandingLMDX Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 50M 100M 150M 200M 250M
LMDX Yearly Total Debt VS Total AssetsLMDX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 200M 400M 600M

2.2 Solvency

Based on the Altman-Z score of -6.66, we must say that LMDX is in the distress zone and has some risk of bankruptcy.
LMDX's Altman-Z score of -6.66 is on the low side compared to the rest of the industry. LMDX is outperformed by 72.86% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -6.66
ROIC/WACCN/A
WACC4.03%
LMDX Yearly LT Debt VS Equity VS FCFLMDX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 0 200M -200M 400M

2.3 Liquidity

A Current Ratio of 1.97 indicates that LMDX should not have too much problems paying its short term obligations.
Looking at the Current ratio, with a value of 1.97, LMDX is doing worse than 74.37% of the companies in the same industry.
LMDX has a Quick Ratio of 1.01. This is a normal value and indicates that LMDX is financially healthy and should not expect problems in meeting its short term obligations.
Looking at the Quick ratio, with a value of 1.01, LMDX is doing worse than 82.41% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 1.97
Quick Ratio 1.01
LMDX Yearly Current Assets VS Current LiabilitesLMDX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 100M 200M 300M 400M

More info and screens

3

3. Growth

3.1 Past

LMDX shows a small growth in Earnings Per Share. In the last year, the EPS has grown by 1.80%.
LMDX shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -68.26%.
Measured over the past years, LMDX shows a very strong growth in Revenue. The Revenue has been growing by 122.52% on average per year.
EPS 1Y (TTM)1.8%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%72.41%
Revenue 1Y (TTM)-68.26%
Revenue growth 3Y122.52%
Revenue growth 5YN/A
Sales Q2Q%-53.02%

3.2 Future

Based on estimates for the next years, LMDX will show a very strong growth in Earnings Per Share. The EPS will grow by 22.53% on average per year.
The Revenue is expected to decrease by -3.56% on average over the next years.
EPS Next Y70.33%
EPS Next 2Y33.38%
EPS Next 3Y22.53%
EPS Next 5YN/A
Revenue Next Year-64.72%
Revenue Next 2Y-27.23%
Revenue Next 3Y-9.52%
Revenue Next 5Y-3.56%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
LMDX Yearly Revenue VS EstimatesLMDX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 100M 200M 300M 400M
LMDX Yearly EPS VS EstimatesLMDX Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 -0.5 -1 -1.5

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for LMDX. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for LMDX. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
LMDX Price Earnings VS Forward Price EarningsLMDX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
LMDX Per share dataLMDX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 -1 -1.5

4.3 Compensation for Growth

LMDX's earnings are expected to grow with 22.53% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y33.38%
EPS Next 3Y22.53%

More info and screens

0

5. Dividend

5.1 Amount

LMDX does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

LUMIRADX LTD

NASDAQ:LMDX (1/8/2024, 8:17:43 PM)

After market: 0.0136 0 (-15%)

0.016

-0.02 (-53.49%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)11-10 2023-11-10/amc
Earnings (Next)03-19 2024-03-19/amc
Inst Owners0.11%
Inst Owner Change0%
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap2.63M
Analysts82.5
Price Target1.22 (7525%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-3.35%
Min EPS beat(2)-12.04%
Max EPS beat(2)5.34%
EPS beat(4)1
Avg EPS beat(4)-35.59%
Min EPS beat(4)-77.22%
Max EPS beat(4)5.34%
EPS beat(8)2
Avg EPS beat(8)-68.43%
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)3.56%
Min Revenue beat(2)-4.17%
Max Revenue beat(2)11.29%
Revenue beat(4)2
Avg Revenue beat(4)3.57%
Min Revenue beat(4)-4.17%
Max Revenue beat(4)11.29%
Revenue beat(8)5
Avg Revenue beat(8)10.8%
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)14.29%
EPS NQ rev (1m)0%
EPS NQ rev (3m)18.42%
EPS NY rev (1m)0%
EPS NY rev (3m)5.85%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0.96%
Revenue NY rev (1m)0%
Revenue NY rev (3m)1.42%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.02
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-1.09
EYN/A
EPS(NY)-0.35
Fwd EYN/A
FCF(TTM)-0.85
FCFYN/A
OCF(TTM)-0.79
OCFYN/A
SpS0.77
BVpS-1.31
TBVpS-1.5
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -99.18%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-54.66%
ROA(5y)-52.33%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score1
Asset Turnover0.37
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 33.03%
Cap/Sales 8.55%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.97
Quick Ratio 1.01
Altman-Z -6.66
F-Score1
WACC4.03%
ROIC/WACCN/A
Cap/Depr(3y)359.47%
Cap/Depr(5y)273.18%
Cap/Sales(3y)27.1%
Cap/Sales(5y)32.2%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)1.8%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%72.41%
EPS Next Y70.33%
EPS Next 2Y33.38%
EPS Next 3Y22.53%
EPS Next 5YN/A
Revenue 1Y (TTM)-68.26%
Revenue growth 3Y122.52%
Revenue growth 5YN/A
Sales Q2Q%-53.02%
Revenue Next Year-64.72%
Revenue Next 2Y-27.23%
Revenue Next 3Y-9.52%
Revenue Next 5Y-3.56%
EBIT growth 1Y-149.06%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year55.43%
EBIT Next 3Y23.29%
EBIT Next 5YN/A
FCF growth 1Y22.35%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-20.46%
OCF growth 3YN/A
OCF growth 5YN/A